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Table 1. Characteristics of subjects and BIA data from different studies in hemodialysis
Study Ikizler [1] Chertow [2] Piccoli [3]
Whole population, N 73 3009 1367
Race-ethnicity
Caucasian 27% 45% 100%
African American 73% 47%
Other 7.7%
Gender 53% Men 53% Men 58% Men
Age years 56 61 60
Height cm — 167 164
Stable, N 5 1116 Unstable, N 5 251HD hemodynamics
Timing of BIA Post-HD Pre-HD Pre-HD Post-HD Pre-HD Post-HD
BMI kg/m2 — 27 24 24 24 24
R Ohm — 498 517 608 543 633
Xc Ohm 49 41 45 61 41 54
Phase angle, 8 — 4.8 5.0 5.7 4.4 4.9
Men, N 39 1589 680 680 118 118
BMI, kg/m2 — 26 24 24 24 24
R Ohm — 460 493 578 505 588
Xc Ohm — 41 44 60 40 51
Phase angle, 8 — 5.1 5.1 5.9 4.5 5.0
Women, N 34 1420 436 436 133 133
BMI kg/m2 — 29 24 24 24 24
R Ohm — 531 554 656 577 673
Xc Ohm — 41 46 62 43 57
Phase angle, 8 — 4.5 4.7 5.4 4.3 4.8
African American, N 53 1411 0 0 0 0
BMI kg/m2 — 27
R Ohm — 491
Xc Ohm — 44
Phase angle, 8 — 5.2
Other, N 20 1598 1116 1116 251 251
BMI kg/m2 — 28 24 24 24 24
R Ohm — 499 517 608 543 633
Xc Ohm — 38 45 61 41 54
Phase angle, 8 — 4.4 5.0 5.7 4.4 4.9
Abbreviations are: BIA, bioelectrical impedance analysis; N, number of subjects; R, resistance; Xc, reactance; BMI, body mass index; HD, hemodialysis.
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Shouldn’t cyclophosphamide be administered always don’t add some MESNA to cyclophosphamide even as
nephrologists? There is some evidence.together with mercaptoethane sulfonate (MESNA)?
Maybe there is a lesson which nephrologists could learn
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